Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 6Unknown 4Active not recruiting 4Terminated 2Not yet recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × lorlatinib × Clear all
NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown
12 enrolled
Lymphoid

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Fondazione Ricerca Traslazionale

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡